Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SLDB

SLDB - Solid Biosciences Inc Stock Price, Fair Value and News

$7.32-0.39 (-5.06%)
Market Closed

Price Targets

SLDB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLDB Price Action

Last 7 days

8.4%

Last 30 days

14.4%

Last 90 days

24.7%

Trailing 12 Months

42.4%

SLDB RSI Chart

SLDB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLDB Valuation

Market Cap

570.3M

Price/Earnings (Trailing)

-3.41

Price/Sales (Trailing)

57.92

Price/Free Cashflow

-4.28

SLDB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

SLDB Fundamentals

SLDB Revenue

Revenue (TTM)

8.1M

SLDB Earnings

Earnings (TTM)

-167.1M

Earnings Growth (Yr)

-39.88%

Earnings Growth (Qtr)

-15.95%

SLDB Profitability

Return on Equity

-76.69%

Return on Assets

-61.02%

Free Cashflow Yield

-23.35%

SLDB Investor Care

Shares Dilution (1Y)

95.00%

Diluted EPS (TTM)

-2.34

SLDB Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202212.2M14.8M11.2M8.1M
202100013.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Solid Biosciences Inc

SLDB
Solid Biosciences Inc., a life science company, engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
 CEO
 WEBSITEsolidbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES87

Solid Biosciences Inc Frequently Asked Questions

SLDB is the stock ticker symbol of Solid Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Solid Biosciences Inc is 570.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, SLDB's PE ratio (Price to Earnings) is -3.41 and Price to Sales (PS) ratio is 57.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLDB PE ratio will change depending on the future growth rate expectations of investors.